Verastem Oncology (VSTM)

1.09 +0.00  +0.00% NASDAQ Nov 11, 15:22 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
03/12/2020 16:30 EDT Misc Verastem Oncology Fourth Quarter Earnings Conference Call in 2019
03/12/2020 Earnings Verastem Oncology Fourth Quarter Earnings in 2019 Release
10/29/2019 16:30 EDT Misc Verastem Oncology Third Quarter Earnings Conference Call for 2019
10/29/2019 Earnings Verastem Oncology Third Quarter Earnings for 2019 Release
08/01/2019 16:30 EDT Misc Verastem Oncology Second Quarter Earnings Conference Call in 2019
08/01/2019 Earnings Verastem Oncology Second Quarter Earnings in 2019 Release
05/14/2019 Misc Verastem Oncology Annual General Meeting in 2018
05/09/2019 16:30 EDT Misc Verastem Oncology First Quarter Earnings Conference Call in 2019
05/09/2019 Earnings Verastem Oncology First Quarter Earnings in 2019 Release
03/12/2019 16:30 EDT Misc Verastem Oncology Fourth Quarter Earnings Conference Call in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: https://www.verastem.com
  • Investor Relations URL: http://phx.corporate-ir.net/phoenix.zhtml?c=250749&p=irol-irhome
  • HQ State/Province: Massachusetts
  • Sector: Healthcare
  • Industry: Biotechnology
  • Equity Style: Small Cap/Value
  • Next Earnings Release: Mar. 12, 2020
  • Last Earnings Release: Oct. 29, 2019
  • Next Ex-Dividend Date: N/A
  • Last Ex-Dividend Date: N/A
  • Description: Verastem Oncology is a part of the healthcare sector. It is a commercial-stage company focused on discovering and developing drugs to aid patients suffering from cancer. The company's first commercial product, COPIKTRA (duvelisib) is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma after at least two prior systemic therapies. The Company's product pipeline candidate, defactinib, is a focal adhesion kinase inhibitor in development for the treatment of cancers where there are limited treatment options, including lung, ovarian, lymphoma, pancreatic and other advanced cancers.

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.